In the corridors of American healthcare, a quiet but profound transformation has occurred. While federal attention has been laser-focused on the specter of immigration and “welfare fraud,” a more systemic, multibillion-dollar financial engine has been quietly siphoning taxpayer funds under the guise of therapeutic care. A deep-dive investigation by The 74 into 275 million Medicaid billing records reveals that Applied Behavior Analysis (ABA)—a controversial, behavior-modification therapy—has become the centerpiece of a lucrative, private equity-backed industry that often prioritizes shareholder returns over the developmental needs of autistic children.
Between 2019 and 2024, Medicaid claims for the six most common autism therapy billing codes surged by 381%, ballooning from $400 million to nearly $2 billion annually. Behind this explosive growth lies not a breakthrough in clinical efficacy, but an aggressive financial strategy orchestrated by private equity firms. By consolidating independent clinics into vast, multi-state networks, these investors have turned autism therapy into a high-volume, low-transparency enterprise, leaving families, educators, and taxpayers to bear the long-term cost.
The Genesis of an Industry
The rise of the ABA industrial complex can be traced back to a grassroots movement in the early 2000s. Driven by a desperate need for coverage, parents—led by advocates like Lorri Unumb—successfully lobbied state legislatures to mandate insurance coverage for ABA. Known as “Ryan’s Law,” these mandates were hailed as a victory for families. By 2014, when the Obama administration clarified that the Affordable Care Act required Medicaid to cover autism treatment, the floodgates opened.
However, the rapid influx of public funding arrived without the necessary regulatory framework. Unlike traditional medical fields, the autism therapy sector grew in a regulatory vacuum, largely allowing practitioners to self-regulate through industry-created boards. This environment of “easy money” and minimal oversight proved irresistible to private equity (PE) firms.
Chronology of Consolidation and Crisis
- 2005–2007: The fight for insurance mandates begins, with South Carolina passing the first major autism insurance law.
- 2014: Federal guidance under the ACA mandates Medicaid coverage for autism, creating a massive, reliable stream of public funding.
- 2015–2024: Private equity firms aggressively enter the market, acquiring 574 sites across 147 providers.
- 2018: Blackstone acquires the Center for Autism and Related Disorders (CARD) for $700 million.
- 2022: Federal audits begin in both red and blue states, uncovering widespread billing irregularities and improper care practices.
- 2023: CARD files for Chapter 11 bankruptcy, citing labor shortages and reimbursement struggles, after having already shuttered more than half its locations.
- 2025–2026: Federal and state legislative bodies scramble to implement oversight as reports of physical abuse and administrative fraud mount.
Supporting Data: The Cost of "Behavior Modification"
The financial data paints a sobering picture of a system skewed toward volume. The 74’s analysis found that during the six-year period from 2019 to 2024, Medicaid paid out $7 billion for ABA therapy. To put that in perspective, that sum is $1 billion more than the total federal investment in the Autism CARES Act—the primary vehicle for funding research and quality-of-life programs—over the last 20 years.
Of the 50 largest ABA providers, 23 are backed by private equity. These firms are disproportionately concentrated in states with “generous” reimbursement policies, such as California, Texas, and Colorado. The data shows that these providers often favor high-intensity, long-duration therapy plans—sometimes up to 40 hours a week—which maximize billable hours regardless of the child’s actual clinical progression or developmental needs.
Federal audits have corroborated these findings. In Colorado, investigators found that 100% of the files they examined contained improper or potentially inappropriate billing. Facilities were caught billing for "one-on-one" therapy while conducting group activities, or billing for custodial tasks like feeding and bathing, which are not reimbursable under medical codes.
The Human Cost: Trauma and Lost Education
Beyond the balance sheets, the human impact is increasingly clear. ABA, pioneered by Ole Ivar Lovaas in the 1960s, is designed to "extinguish" autistic traits, such as hand-flapping or rocking, to ensure compliance with neurotypical behaviors. Many autistic adults, including those who have undergone the therapy, draw direct parallels between ABA and LGBTQ conversion therapy, both of which were rooted in the same philosophy of behavior conditioning.
Furthermore, the "therapy-as-schooling" model has created a secondary crisis: the loss of academic instruction. Medicaid-funded therapy centers are not schools, yet many children spend their formative years in these centers, effectively isolated from their peers and denied the legally mandated education they would receive in a public school setting. Audit reports have highlighted cases of children remaining in these centers for years, missing out on literacy, social development, and the fundamental right to an inclusive education.
Official Responses and Defensive Posturing
The private equity industry maintains that its involvement provides necessary infrastructure and scale. In a statement regarding the bankruptcy of CARD, Blackstone noted that it was never involved in clinical decisions and sought only to keep facilities open during a "perfect storm" of economic challenges.
Similarly, Centria Healthcare, a major Medicaid biller acquired by Thomas H. Lee Partners, has consistently defended its operations. CEO David Harbour emphasized a commitment to "ethical care" and "clinical quality." However, historical investigations, including reports from the Detroit Free Press, have detailed allegations of billing fraud and child abuse within these large-scale networks.
Proponents of the industry argue that "bad actors" are the exception rather than the rule. Lorri Unumb, now CEO of the Council of Autism Service Providers, asserts that the vast majority of providers are ethical and that the industry must be allowed to self-police to maintain standards.
Implications: A Future at Risk
The current political climate has only deepened the uncertainty. With the incoming Trump administration and the Department of Government Efficiency (DOGE) targeting Medicaid spending, there is a legitimate fear that legitimate services may be slashed alongside fraudulent ones.
Advocates like Ari Ne’Eman, former director of the Autistic Self-Advocacy Network, argue that the industry’s flaws were baked into the system from the beginning. "Private equity didn’t corrupt a fine field," Ne’Eman notes. "They entered because the flaws were already there."
The legislative response has been mixed. In Colorado, a new law aimed at curbing abuse was recently signed, yet it notably failed to include independent oversight from mental health professionals or the autistic community itself, instead keeping power largely within the hands of the ABA industry.
For parents of autistic children, the system remains a minefield. The pressure to choose between "cures" and "care" is immense, and the lack of transparent, independent data on the long-term efficacy of ABA makes informed consent nearly impossible. As federal spending on ABA continues to dwarf investment in programs that support the actual quality of life for autistic individuals, the question remains: who is this system truly serving?
The evidence suggests that as long as the current financial incentives remain, the children—and the taxpayers—will continue to pay the price for a model of care that prioritizes profit over the humanity of those it claims to help. The coming years will serve as a critical test of whether the American healthcare system can decouple the profit motive from the developmental rights of its most vulnerable citizens.
